These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 9351529)

  • 1. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with prophylaxis in Sweden.
    Nilsson IM
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
    Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
    Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing bleed frequency and factor concentrate use between haemophilia A and B patients.
    Nagel K; Walker I; Decker K; Chan AK; Pai MK
    Haemophilia; 2011 Nov; 17(6):872-4. PubMed ID: 21342368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
    Ahnström J; Berntorp E; Lindvall K; Björkman S
    Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia.
    Lowe GD
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of implantable venous access devices in children with severe hemophilia: benefits and burden.
    Van Dijk K; Van Der Bom JG; Bax KN; Van Der Zee DC; Van Den Berg MH
    Haematologica; 2004 Feb; 89(2):189-94. PubMed ID: 15003894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central venous access catheters in children with haemophilia.
    Blanchette VS; al-Musa A; Stain AM; Filler RM; Ingram J
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central venous access devices in children with hemophilia: an update.
    Blanchette VS; Al-Musa A; Stain AM; Ingram J; Fille RM
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S11-4. PubMed ID: 9351530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
    Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
    Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
    Thornburg CD; Pipe SW
    Haemophilia; 2006 Mar; 12(2):198-9. PubMed ID: 16476098
    [No Abstract]   [Full Text] [Related]  

  • 18. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of haemophilic synovitis: prophylaxis.
    Lee CA
    Haemophilia; 2007 Nov; 13 Suppl 3():20-5. PubMed ID: 17822517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
    Berntorp E
    Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.